Abstracts Archive - Page 749 of 2607 - ACR Meeting Abstracts

Abstract Number: 0658 • ACR Convergence 2021
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Rebecca Overbury¹, Kelly Huynh², Tracy Frech¹, John Bohnsack¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²Intermountain Health Care, Salt Lake City, UT
Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
Abstract Number: 0659 • ACR Convergence 2021
Understanding the Rheumatologic Population We Serve Through Objective Analysis of Referrals and Diagnoses: Does Perception Match Actual Data?
Kirsten Koons¹, Jonida Cote², Sanjeev Shrestha³, Melissa Band³, David Pugliese⁴ and Eric Newman³, ¹Geisinger Medical Center, Lewisburg, PA, ²Geisinger Medical Center, Orefield, PA, ³Geisinger Medical Center, Danville, PA, ⁴Geisinger Medical Center, Wilkes Barre, PA
Background/Purpose: Healthcare access in our Rheumatology Department is challenging. Fibromyalgia is perceived to occupy a large portion of clinic visits, leading to increased wait times…
Abstract Number: 0660 • ACR Convergence 2021
Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
Kazuki Yoshida, Tianrun Cai, Lily G. Bessette, Erin Kim, Su Been Lee, Luke E. Zabotka, Alec Sun, Jun Liu, DH Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recurrent gout flares are the most crucial outcome in studies of gout treatment. However, gout flares is challenging to identify in a large population…
Abstract Number: 0661 • ACR Convergence 2021
Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Lisa Stamp¹, Rebecca Grainger², Chris Frampton¹, Jill Drake¹ and Catherine Hill³, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Wellington, New Zealand, ³Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), also known as omega-3 fats act as alternate COX substrates to arachidonic acid (AA). Their metabolism results…
Abstract Number: 0662 • ACR Convergence 2021
Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials
Lisa Stamp¹, Chris Frampton¹, Melanie Morillon², William Taylor³, Nicola Dalbeth⁴, Jasvinder Singh⁵, Micheal Doherty⁶, Weiya Zhang⁶, Helen Richardson⁶, Aliya Sarmanova⁷ and Robin Christensen⁸, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²Odense University Hospital, Odense, Denmark, ³University of Otago, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nottingham, Nottingham, United Kingdom, ⁷University of Bristol Medical School, Bristol, United Kingdom, ⁸Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark
Background/Purpose: Use of serum urate (SU) as a treatment target and outcome measure has become controversial in light of the American College of Physician Gout…
Abstract Number: 0663 • ACR Convergence 2021
Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout
Quint Soto¹, Alison Petro¹, Bryant England¹, Harlan Sayles¹, Lindsay Helget¹, Punyasha Roul¹, Tuhina Neogi², James O'Dell¹, Brian LaMoreaux³ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Gout is associated with a number of comorbidities such as diabetes that are known risk factors for peripheral vascular disease. These comorbidities along with…
Abstract Number: 0664 • ACR Convergence 2021
Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study
Jeremy Holyer¹, William Taylor², Angelo Gaffo³, Graham Hosie¹, Anne Horne¹, Borislav Mihov¹, Isabel Su¹, Gregory Gamble¹, Nicola Dalbeth¹ and Sarah Stewart¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago Wellington, Auckland, New Zealand, ³University of Alabama at Birmingham Medical Centre, Birmingham, AL
Background/Purpose: Several factors contribute to the patient experience of gout flares, including pain intensity, duration, frequency, and disability. It is unknown which of these factors…
Abstract Number: 0665 • ACR Convergence 2021
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
Abdul Abdellatif¹, Lin Zhao², Paul M. Peloso³, Katya Cherny², Brad Marder², John D. Scandling⁴ and Kenneth Saag⁵, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics plc, Gurnee, IL, ⁴Stanford Medicine, Department of Nephrology, Stanford, CA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and is a…
Abstract Number: 0666 • ACR Convergence 2021
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
Mark Russell¹, Benjamin Ellis², Benjamin Clarke¹, Deepak Nagra¹ and James Galloway³, ¹King's College London, London, United Kingdom, ²Imperial College Healthcare NHS Trust, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: Hospital admissions for gout flares have increased dramatically in recent years. Strategies to reduce hospitalizations and improve uptake of urate-lowering therapy (ULT) are needed.…
Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Silvia Ruiz-Simón¹, Irene Calabuig², Miguel Gómez-Garberí³ and MARIANO ANDRES⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital General Universitario de Alicante, Alicante, Spain, ³Hospital Universitario San Juan de Alicante, San Juan de Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…
Abstract Number: 0668 • ACR Convergence 2021
Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence
Min Kyung Chung¹, Sung Soo Kim², Yun-Hong Cheon³, Seung Jae Hong⁴, Hyo Jin Choi⁵, Mi Ryoung Seo⁵, Ji Won Hwang⁶, Joong Kyong Ahn⁷, Sang-Heon Lee⁸, Hong Ki Min⁸, Hoon-Suk Cha⁹, Shin-Seok Lee¹⁰, Jennifer Lee¹¹, Ki Won Moon¹², Chang-Keun Lee¹³, Hyun-Ok Kim¹⁴, Young Sun Seo¹⁵, Seung-Cheol Shim¹⁶, Seong Wook Kang¹⁶, Jinhyun Kim¹⁶, Sang Tae Choi¹⁷, Jung Soo Song¹⁷ and Jisoo Lee¹, ¹Ewha Womans University College of Medicine, Seoul, Republic of Korea, ²Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea, ³Gyeongsang National University Hospital, Jinju, Republic of Korea, ⁴Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Republic of Korea, ⁵Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ⁶Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea, ⁷Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁸Konkuk University Medical Center, Seoul, Republic of Korea, ⁹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ¹⁰Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ¹¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, ¹²Kangwon National University School of Medicine, Chuncheon, Republic of Korea, ¹³Asan Medical Center, SEOUL, Republic of Korea, ¹⁴Gyeongsang National University College of Medicine, Changwon, Republic of Korea, ¹⁵Gyeongsang National University Hospital, Changwon, Republic of Korea, ¹⁶Chungnam National University, Chungnam National University Hospital, Daejeon, Republic of Korea, ¹⁷Chung-Ang University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Patient-centered management is becoming increasingly important in gout, but there are limited studies exploring patients’ perspectives and preferences. We aimed to investigate patients’ perspectives…
Abstract Number: 0669 • ACR Convergence 2021
Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
Anthony Amatucci¹, Brian LaMoreaux² and David Bulbin³, ¹Horizon Therapeutics, West Orange, NJ, ²Horizon Therapeutics plc, Deerfield, IL, ³Geisinger Health System, Danville, PA
Background/Purpose: Data suggests that the number of patients with early-onset gout (EOG), defined as patients under the age of 40 years, is increasing1. There is…
Abstract Number: 0670 • ACR Convergence 2021
Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone
Jennifer Velasco, Claudia Gohr, Elizabeth MItton-Fitzgerald and Ann Rosenthal, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Hemochromatosis (HH) is one of the strongest known risk factors for calcium pyrophosphate (CPP) crystal deposition. The pathogenic mechanisms causing CPP crystal formation in…
Abstract Number: 0671 • ACR Convergence 2021
Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
Aaron Broadwell¹, John Albert², Brian LaMoreaux³ and Lissa Padnick-Silver³, ¹Rheumatology and Osteoporosis Specialists, Shreveport, LA, ²Rheumatic Disease Center, Milwaukee, WI, ³Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Patients with uncontrolled or refractory gout have heavy disease burden,1 but few treatment options. Pegloticase is effective for lowering serum urate (SU) in these…
Abstract Number: 0672 • ACR Convergence 2021
Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
Chio Yokose¹, Natalie McCormick², Na Lu³, Amit Joshi² and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Two recent analyses of the Global Burden of Disease Study reported on the rising global burden of gout (Safiri A&R 2020, Xia Rheumatology 2020).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].